EUVIMEDEUVIMED entdecken
Crossref

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Harold J Burstein iD, Angela DeMichele iD, Lesley Fallowfield, Mark R Somerfield iD, N Lynn Henry iD, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Canc…

Journal of Clinical Oncology · 20.04.2024 · 42 (12) · 1450-1453

DOI: 10.1200/jco.24.00248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2024. Verfasst von Harold J Burstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dana Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansFulvestrantPyrimidinesPyrrolesErb-b2 Receptor Tyrosine Kinases

Substanzen

FulvestrantPyrimidinesPyrrolesErb-b2 Receptor Tyrosine KinasescapivasertibERBB2 protein, human

Autor:innen und Institutionen

  • Dana Farber Cancer Institute, Boston, MA.
  • University of Pennsylvania, Philadelphia, PA.
  • University of Sussex, Brighton, United Kingdom.
  • American Society of Clinical Oncology, Alexandria, VA.
  • University of Michigan, Ann Arbor, MI.

ORCID-Profile: Harold J Burstein, Angela DeMichele, Mark R Somerfield, N Lynn Henry

Zitieren

APA

Burstein, H. J., DeMichele, A., Fallowfield, L., Somerfield, M. R., Henry, N. L., Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, & Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Canc… (2024). Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of Clinical Oncology, 42(12), 1450-1453. https://doi.org/10.1200/jco.24.00248

Vancouver

Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, et al. Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of Clinical Oncology. 2024;42(12):1450-1453. doi:10.1200/jco.24.00248

BibTeX
@article{Burstein2024,
  author = {Burstein, Harold J and DeMichele, Angela and Fallowfield, Lesley and Somerfield, Mark R and Henry, N Lynn and Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels and Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Canc…, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Canc…},
  title = {Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {12},
  pages = {1450--1453},
  doi = {10.1200/jco.24.00248}
}
Kostenlos starten →